Mitotane: Difference between revisions

	WikiDoc Resources for Mitotane
Articles
Most recent articles on Mitotane Most cited articles on Mitotane Review articles on Mitotane Articles on Mitotane in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mitotane Images of Mitotane Photos of Mitotane Podcasts & MP3s on Mitotane Videos on Mitotane
Evidence Based Medicine
Cochrane Collaboration on Mitotane Bandolier on Mitotane TRIP on Mitotane
Clinical Trials
Ongoing Trials on Mitotane at Clinical Trials.gov Trial results on Mitotane Clinical Trials on Mitotane at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mitotane NICE Guidance on Mitotane NHS PRODIGY Guidance FDA on Mitotane CDC on Mitotane
Books
Books on Mitotane
News
Mitotane in the news Be alerted to news on Mitotane News trends on Mitotane
Commentary
Blogs on Mitotane
Definitions
Definitions of Mitotane
Patient Resources / Community
Patient resources on Mitotane Discussion groups on Mitotane Patient Handouts on Mitotane Directions to Hospitals Treating Mitotane Risk calculators and risk factors for Mitotane
Healthcare Provider Resources
Symptoms of Mitotane Causes & Risk Factors for Mitotane Diagnostic studies for Mitotane Treatment of Mitotane
Continuing Medical Education (CME)
CME Programs on Mitotane
International
Mitotane en Espanol Mitotane en Francais
Business
Mitotane in the Marketplace Patents on Mitotane
Experimental / Informatics
List of terms related to Mitotane

Mitotane
Clinical data
Pregnancy; category	C;
Routes of; administration	oral (500mg tablets)
ATC code	L01XX23 (WHO) ;
Legal status
Legal status	presciption required;
Pharmacokinetic data
Bioavailability	40%
Protein binding	6%
Elimination half-life	18 to 159 days
Identifiers
	IUPAC name 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene;
CAS Number	53-19-0;
PubChem CID	4211;
DrugBank	APRD00494;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C14H10Cl4
Molar mass	320.04 g/mol

← Older edit Newer edit →

VisualWikitext

Revision as of 19:37, 4 September 2012

Overview

Mitotane, or o,p'-DDD, is a medication used in the treatment of the rare disease adrenocortical carcinoma. It is an isomere chemically to DDT and is a derivative of DDD.^[1]

It has been produced by Bristol Myers Squibb SpA but it is marketed as an orphan drug due to the small number of patients in need of it. Its administration occurs in cases where the tumour cannot be surgically omitted. A 2007 study of 177 patients shows a significant increase in the recurrence-free interval after radical surgery followed by Mitotane when compared to surgery alone.^[2]

Mitotane alternates steroides peripheral metabolism, represses directly the adrenal cortex and alternates cortisone metabolism leading to hypocortisolism. Side effects as reported by Schteinberg et al. include anorexia and nausea (88%), diarrhea (38%), vomiting (23%), decreased memory and ability to concentrate (50%), rash (23%), gynecomastia (50%), arthralgia (19%), and leukopenia (7%).^[3]

Its trade name is Lysodren.

Veterinary use

Mitotane is also used to treat pituitary-dependent Cushing's syndrome in canines. The medication is used in the controlled destruction of adrenal tissue, leading to a decrease in cortisol production.^[4]

References

↑ Information from PubChem
↑ Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. "Adjuvant mitotane treatment for adrenocortical carcinoma". N Engl J Med. 2007 Jun 7;356(23):2372-80.
↑ Schteinberg DE, Motazedi A, NoonanRA, Thompson NW. "Treatment of Adrenal Carcinomas". Arch.Surg. (1982) 117:1142-9.
↑ Canine Cushing’s Syndrome: Diagnosis and Treatment

External links

de:Mitotane

Template:WH Template:WikiDoc Sources

[PubChem-1] Information from PubChem

[2] Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. "Adjuvant mitotane treatment for adrenocortical carcinoma". N Engl J Med. 2007 Jun 7;356(23):2372-80.

[3] Schteinberg DE, Motazedi A, NoonanRA, Thompson NW. "Treatment of Adrenal Carcinomas". Arch.Surg. (1982) 117:1142-9.

[4] Canine Cushing’s Syndrome: Diagnosis and Treatment

[1]

[2]

[3]

[4]

@@ Line 15: / Line 15: @@
 ==References==
-<div class="references-small"><references /></div>
+<div class="references-small">{{reflist|2}}</div>
 ==External links==

v t e Chemotherapeutic agents/Antineoplastic agents (L01)
Alkylating and alkylating-like agents	Nitrogen mustards: (Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Bendamustine, Uramustine) Nitrosoureas:(Carmustine, Fotemustine, Lomustine, Streptozocin) Platinum (alkylating-like): (Carboplatin, Cisplatin, Oxaliplatin, Triplatin tetranitrate, Satraplatin) Alkyl sulfonates:(Busulfan, Treosulfan) Hydrazines:(Procarbazine, Dacarbazine, Temozolomide) Aziridines:(ThioTEPA)
Antimetabolites	Folic acid: (Aminopterin, Methotrexate, Pemetrexed, Raltitrexed). Purine:(Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Pentostatin, Thioguanine) Pyrimidine:(Capecitabine, Cytarabine, Decitabine, Fluorouracil, Floxuridine, Gemcitabine)
Spindle poison/mitotic inhibitor	Taxane: (Docetaxel, Larotaxel, Paclitaxel). Vinca: (Vinblastine, Vincristine, Vindesine, Vinorelbine).
Cytotoxic/antitumor antibiotics	Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Pixantrone, Valrubicin) streptomyces (Actinomycin, Bleomycin, Mitomycin, Plicamycin) - Hydroxyurea
Topoisomerase inhibitors	Camptotheca: (Camptothecin, Topotecan, Irinotecan, Rubitecan), Podophyllum:(Etoposide, Teniposide)
CI monoclonal antibodies	Receptor tyrosine kinase (Cetuximab, Panitumumab, Trastuzumab) - CD20 (Rituximab, Tositumomab) - other (Alemtuzumab, Bevacizumab, Gemtuzumab)
Photosensitizers	Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, Verteporfin
Tyrosine kinase inhibitors	Axitinib, Bosutinib, Cediranib, Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, Vandetanib
Cyclin-dependent kinase inhibitor	Seliciclib
Other	retinoids (Alitretinoin, Tretinoin), Fusion protein (Aflibercept) - Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase (Pegaspargase), Bexarotene, Bortezomib, Celecoxib, Denileukin diftitox, Elesclomol, Estramustine, Irofulven, Ixabepilone, Masoprocol, Mitotane, Oblimersen, Testolactone, Tipifarnib, Trabectedin

Mitotane: Difference between revisions

Revision as of 19:37, 4 September 2012

Contents

Overview

Veterinary use

References

External links

Navigation menu

Clinical data
Pregnancy category	C
Routes of administration	oral (500mg tablets)
ATC code	L01XX23 (WHO)
Legal status
Legal status	presciption required
Pharmacokinetic data
Bioavailability	40%
Protein binding	6%
Elimination half-life	18 to 159 days
Identifiers
IUPAC name 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene
CAS Number	53-19-0
PubChem CID	4211
DrugBank	APRD00494
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₄H₁₀Cl₄
Molar mass	320.04 g/mol

Mitotane: Difference between revisions

Revision as of 19:37, 4 September 2012

Overview

Veterinary use

References

External links

Navigation menu

Search